HN21C0617

Development of eIF4E ASO treating childhood intractable epilepsy as a first-in-class drug and establishment of R&D environment for RNA therapeutics

Sovargen Co.,Ltd
SoVarGen
Somatic Variations Genomics

NEUROSCIENCE | **Non-Clinical**

Product Type	Anti-sense Oligonucleotides (RNA Therapeutics)
Indication	Control and management of seizures in Focal Cortical Dysplasia type II (FCD T2) patients who are refractory to neuro-surgery
Target	eIF4E
MoA(Mechanism of Action)	• Brain somatic mutations in mTOR pathway (mTORopathy) genes leads to hyperactivation of eIF4E activity, resulting in abnormal protein translation which is causative for epilepsy. • SVG102 complementarily binds to eIF4E mRNA, leading to its degradation by RNase H cleavage. 
Competitiveness	First-in-class • No available drug for FCD T2 epilepsy patients • Neuro-surgery is the only option but 40% of surgery patients still have seizures (refractory to neuro-surgery) Potential for other disease • Potential to expand the indication to mTORopathy disease such as Tuberous Sclerosis Complex (TSC) epilepsy patients
Development Stage	Pre-Clinical Stage (US IND filing is planned in 2023)
Route of Administration	Intrathecal administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund